Efficacy of postoperative mitomycin-C eye drops on the clinical outcome in endoscopic dacryocystorhinostomy

Jae Rock Do, Hwa Lee, Se Hyun Baek, Tae Soo Lee, Minwook Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. Design: Retrospective, nonrandomized, interventional case series. Methods: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 % MMC for 5 min. Group 2 was treated with 0.02 % MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. Results: The success rate showed no significant difference among the three groups (P =.122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P =.419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P =.041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P =.022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P =.308, P =.881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. Conclusion: Use of postoperative topical 0.02 % MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.

Original languageEnglish
Pages (from-to)785-790
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume254
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Dacryocystorhinostomy
Ophthalmic Solutions
Mitomycin
Granuloma
Nasolacrimal Duct
Inflammation
Silicones

Keywords

  • Dacryocystorhinostomy
  • Endoscopy
  • Mitomycin
  • Nasolacrimal duct

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Efficacy of postoperative mitomycin-C eye drops on the clinical outcome in endoscopic dacryocystorhinostomy. / Do, Jae Rock; Lee, Hwa; Baek, Se Hyun; Lee, Tae Soo; Chang, Minwook.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 254, No. 4, 01.04.2016, p. 785-790.

Research output: Contribution to journalArticle

@article{74ab591512b944dbb42fccfda0f2665c,
title = "Efficacy of postoperative mitomycin-C eye drops on the clinical outcome in endoscopic dacryocystorhinostomy",
abstract = "Purpose: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. Design: Retrospective, nonrandomized, interventional case series. Methods: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 {\%} MMC for 5 min. Group 2 was treated with 0.02 {\%} MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. Results: The success rate showed no significant difference among the three groups (P =.122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P =.419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P =.041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P =.022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P =.308, P =.881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. Conclusion: Use of postoperative topical 0.02 {\%} MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.",
keywords = "Dacryocystorhinostomy, Endoscopy, Mitomycin, Nasolacrimal duct",
author = "Do, {Jae Rock} and Hwa Lee and Baek, {Se Hyun} and Lee, {Tae Soo} and Minwook Chang",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s00417-015-3229-2",
language = "English",
volume = "254",
pages = "785--790",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Efficacy of postoperative mitomycin-C eye drops on the clinical outcome in endoscopic dacryocystorhinostomy

AU - Do, Jae Rock

AU - Lee, Hwa

AU - Baek, Se Hyun

AU - Lee, Tae Soo

AU - Chang, Minwook

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. Design: Retrospective, nonrandomized, interventional case series. Methods: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 % MMC for 5 min. Group 2 was treated with 0.02 % MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. Results: The success rate showed no significant difference among the three groups (P =.122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P =.419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P =.041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P =.022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P =.308, P =.881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. Conclusion: Use of postoperative topical 0.02 % MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.

AB - Purpose: To evaluate the effect of postoperative topical mitomycin-C (MMC) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative MMC soaking. Design: Retrospective, nonrandomized, interventional case series. Methods: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02 % MMC for 5 min. Group 2 was treated with 0.02 % MMC eye drops for 5 days after surgery, without intraoperative application of MMC. Group 3 was the control group of cases without the use of MMC. Each group was evaluated for surgical success, presence of complications including granuloma, synechiae, and tube-induced inflammation, and the adverse effect of the MMC at least 6 months after the surgery. Results: The success rate showed no significant difference among the three groups (P =.122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P =.419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P =.041, chi-square analysis). The presence of granuloma was significantly lower in Group 1 than in the other two groups (P =.022, chi-square analysis). Synechiae and silicone tube-induced inflammation were not significantly different (P =.308, P =.881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative MMC application. Conclusion: Use of postoperative topical 0.02 % MMC is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.

KW - Dacryocystorhinostomy

KW - Endoscopy

KW - Mitomycin

KW - Nasolacrimal duct

UR - http://www.scopus.com/inward/record.url?scp=84961215489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961215489&partnerID=8YFLogxK

U2 - 10.1007/s00417-015-3229-2

DO - 10.1007/s00417-015-3229-2

M3 - Article

VL - 254

SP - 785

EP - 790

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 4

ER -